| |
NewswireToday - /newswire/ -
Atlanta, GA, United States, 05/18/2009 - A new report from leading life sciences advisory firm TSG highlights the current climate and major challenges for companies in the $504 million dollar market for stem cell research, discovery & biotools.
|
| |
The stem cell research, discovery and biotools market surpassed half a billion dollars in 2008, and is growing at nearly 17% per year. TSG, a global leader in strategic advisory for the life sciences, has profiled this category in a new report highlighting the current climate and major challenges for companies seeking to establish leadership in this emerging market.
While the March 2009 repeal of restrictions on NIH funding of human embryonic stem cell lines brought stem cell therapeutics back into the spotlight for public policy makers, it’s the stem cell research and biotools market which has emerged as top of mind for many VC, Biotech and Pharma players. TSG has reviewed the current political and investment climate in stem cell research, discovery, and biotools, as well as key hurdles around cell sourcing, biomanufacturing, IP, and business model development.
The report also highlights recent moves by major therapeutic, pharma, and tools companies in the last 12 months to develop strategic alliances and partnerships around both bioproduction and cell therapies. TSG's overview of financing and M&A activity by stem cell companies over the same period provides a critical overview of transaction activity. In addition, TSG believes that many of the challenges faced by tools and service companies will be paralleled or even amplified for therapy-focused stem cell companies and the regenerative medicine community at large.
"Both stem cell tools and therapies are still at an early stage, but the next two years will set the tone," says TSG CEO Panna Sharma. "Many companies founded with therapeutic ambitions are having to re-evaluate their business models, and will look to partnerships, licensing and collaborations to develop processes and joint IP in the research and biotools space." TSG views the current climate as a unique opportunity for both innovative entrants to address unmet customer needs and external players looking to consolidate existing companies and technologies.
The report is available for download at tsg-partners.com, along with information on TSG's ten proprietary indices in the life sciences and nutrasciences. Individuals interested in learning more about TSG's life sciences coverage can also register to receive weekly market updates across TSG's Lab Services, Drug Discovery / BioTools, Molecular Diagnostics, Global Diagnostics, and Point of Care indices.
About TSG
TSG (tsg-partners.com) is a specialty advisory group that combines growth strategy and corporate finance to create shareholder value for companies in the life sciences, biotechnology, healthcare, and wellness sectors. TSG’s approach is based on a combination of independent analysis of the markets and customer needs and a deep appreciation of the technology landscape and capital markets environment. TSG’s sole focus is on bringing together growth strategy and transaction insight to build sector leaders in life sciences. TSG has presence in Atlanta, Boston, New York and Silicon Valley and was founded in 2001 by Panna Sharma.
|
laura[.]tsg-partners.com 
